Kevin C. Johnson - Concepedia

Author

Kevin C. Johnson

Pfizer (United States)ORCID

Also Known As

K JOHNSON, Kevin C. Johnson, Kevin Charles Johnson, Kevin Johnson

Publications

878

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Intel (United States)

About

Kevin C. Johnson is an author at Pfizer (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	127
2	Engineering	2	2	99
3	Natural Sciences	2	2	81
4	Biochemistry	1	1	39
5	Biomedical Engineering	1	1	57

Kevin C. Johnson

Publications

866

Citations

H-Index

Page 1

	Year	Citations
The effect of particle size distribution on dissolution rate and oral absorption Raymond L. Hintz, Kevin C. Johnson International Journal of Pharmaceutics Particle Size DistributionDissolution RateOral AbsorptionParticle TechnologyPowder Compaction	1989	323
Guidance in the Setting of Drug Particle Size Specifications to Minimize Variability in Absorption Kevin C. Johnson, Archie C. Swindell Pharmaceutical Research	1996	195
Dissolution Modeling: Factors Affecting the Dissolution Rates of Polydisperse Powders Allan T. K. Lu, Mary E. Frisella, Kevin C. Johnson Pharmaceutical Research	1993	162
Dissolution and Absorption Modeling: Model Expansion to Simulate the Effects of Precipitation, Water Absorption, Longitudinally Changing Intestinal Permeability, and Controlled Release on Drug Absorption Kevin C. Johnson Drug Development and Industrial Pharmacy EngineeringModel ExpansionBiomedical EngineeringDigestive TractPhysiologically-based Pharmacokinetic Modeling	2003	57
Comparison of Methods for Predicting Dissolution and the Theoretical Implications of Particle-Size-Dependent Solubility Kevin C. Johnson Journal of Pharmaceutical Sciences Materials ScienceEngineeringColloidal SystemPhysicsPhase Equilibrium	2011	42
Discovery of Trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as Potent, Orally Bioavailable TGR5 (GPBAR1) Agonists: Structure–Activity Relationships, Lead Optimization, and Chronic In Vivo Efficacy Dean P. Phillips, Wenqi Gao, Yang Yang‐Hartwich, Journal of Medicinal Chemistry Pharmaceutical SciencePharmacotherapyOrally Bioavailable Tgr5Structure–activity RelationshipsInsulin Signaling	2014	39
Meeting Report: Applied Biopharmaceutics and Quality by Design for Dissolution/Release Specification Setting: Product Quality for Patient Benefit Arzu Selen, María T. Cruañes, Anette Müllertz, The AAPS Journal Pharmaceutical FormulationBioequivalenceMedicineProduct QualityPharmacotherapy	2010	31
The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties Tony Siu, Jason D. Brubaker, Peter H. Fuller, Journal of Medicinal Chemistry	2017	17

Page 1